Actinogen Medical (ASX:ACW) has received positive scientific advice from the European Medicines Agency (EMA) for its Alzheimer’s disease program, aligning closely with earlier guidance from the US Food and Drug Administration (FDA). The development provides the Company with a clearer pathway toward potential marketing approvals in two major global pharmaceutical markets.

🧠 EMA supports Actinogen Medical’s proposed development pathway for Xanamem® (emestedastat), including one additional pivotal phase 3 trial using a 10mg dose versus placebo following positive XanaMIA trial results.

🌍 Guidance from the EMA closely aligns with prior FDA feedback, giving Actinogen regulatory clarity across both Europe and the United States as it advances discussions with potential development and commercialisation partners.

📊 The EMA also supported the broadening of inclusion criteria for future trials to include more patients with moderate Alzheimer’s disease, while confirming the proposed safety database and additional supporting studies required for a future marketing application.

Actinogen Medical CEO and Managing Director Dr Steven Gourlay commented:

“We are pleased with the clear guidance from the EMA that closely conforms with our plans for streamlined development of Xanamem in Alzheimer’s disease, as agreed previously with the FDA. Importantly, the EMA agreed with our approach for only one additional, pivotal trial using a single 10 mg Xanamem dose versus placebo to support a marketing application for Alzheimer’s in the EU.”

When did you last book a flight through a travel agent - not Google, or the airline directly - but a travel agent? ASX-listed Web Travel Group (ASX:WEB), owner of online travel agent Webjet, is having a rough year with the stock down 45% year to date.

Webjet is facing multiple headwinds at once, as referenced in its FY26 results presentation. Virgin Australia Holdings (ASX:VGN) has just cut its commissions for Webjet so that Virgin can go direct to customers. Webjet’s CEO has quit and the Iran war has pushed up oil prices, disrupting travel plans.

#travel #stocks #fintok #flying #money

Pengana Private Equity Trust (ASX:PE1) offers investors access to global private equity and private credit through a listed ASX structure. Managed with Grosvenor Capital Management, PE1 targets diversified institutional-quality investments across healthcare, hospitality and global growth sectors. William Dougall, Investment Specialist at Pengana Capital Group, discusses recent portfolio additions and how PE1 balances long-term opportunities with short-term currency impacts.

📊 Market backdrop
📈 Performance and portfolio quality
🏆 Top 10 holdings

What has Robinhood Markets Inc (NASDAQ:HOOD) revealed that would have sounded like science fiction five years ago? Two things:

1. The trading app said that users can now connect AI agents directly to their brokerage accounts to monitor markets, execute trades and rebalance portfolios.
2. Robinhood is also offering users an Agentic Credit Card. If you tell it: `Buy me those sneakers whenever they drop under $200,’ done. The AI can invest and shop for you, all on autopilot.

Is this the future? Perhaps, but Robinhood notes in the fine print that AI agents could also lose money when trading. As with any investment, there are risks involved.

#tech #stocks #trading #investing #AI

Epiminder (ASX:EPI), a medical device company developing continuous brain monitoring technology for epilepsy, has reached 25 patient enrolments in its DETECT US clinical study. DETECT is a prospective, randomised, controlled study supporting reimbursement for the Minder® System. Around 20 leading US sites are now active, including Mayo Clinic, Harvard, Stanford, Yale, Duke and the University of Pennsylvania, with enrolment accelerating as activation expands. CEO Rohan Hoare joins Lel Smits from The Stock Network to discuss what this patient enrolment milestone signals for trial execution, how site expansion is translating into recruitment, and the next key inflection points for investors.

🏥 Site expansion translating into enrolment growth
⚕️ Scaling toward critical trial thresholds
🩺 Epiminder signal quality featured in publication
🔬 Epiminder Director alignment

NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has reported exceptional early outcomes from patients treated with its StemSmart™ mesenchymal stem cell therapy under the Company’s Special Access Program. Four of the five patients receiving the treatment had a successful clinical response in fistulising Crohn’s disease.

💉 StemSmart™ delivered strong early clinical outcomes, with all five patients treated under the Special Access Program showing improvement and 80% achieving a successful clinical response, while no serious adverse events were reported.

🧬 NeuroScientific is advancing development of a dedicated Australian Phase 2 clinical trial in fistulising Crohn’s disease, expected to commence in the second half of calendar 2026 and support the Company’s pathway toward future Marketing Authorisation.

📈 The Company believes StemSmart™ has broader platform potential across multiple inflammatory conditions, with opportunities extending beyond Crohn’s disease into organ transplant immune tolerance, lung inflammatory disease and graft-versus-host disease.

NeuroScientific Biopharmaceuticals Chief Executive Officer, Nathan Smith, commented: “The pivotal data generated from this planned trial will assist NSB in its aim to obtain Marketing Authorisation for StemSmart™ to potentially benefit Australian patients and provide a pathway to commercialisation of our technology earlier than previously forecasted.”

Far East Gold (ASX:FEG) is advancing its flagship Idenburg Gold Project in Papua Province, Indonesia, as the company transitions from exploration into development planning. With a 44% increase in the project’s JORC Mineral Resource to 780,000 ounces of gold, advancing permitting, strong community support and a Scoping Study now underway, the foundations are coming together for the project’s next phase of growth. Far East Gold Managing Director & CEO, Shane Menere, joins Lel Smits from The Stock Network to discuss Idenburg’s development pathway, upcoming catalysts and the company’s evolving understanding of project economics.

🪓 From explorer to emerging producer
⚒️ What the market still isn’t seeing in FEG
🛘 Why Idenburg could be Far East Gold`s defining development asset
🔎 Outlook, catalysts & next steps

Westpac Banking Corp (ASX:WBC) has been ordered to pay $26 million in civil penalties after failing to respond to more than 200 customer hardship requests within legal timeframes between 2017 and 2023.

The affected customers included those facing domestic abuse, illness, job losses and natural disasters, were seeking support on home loans, credit cards and personal loans.

The court found Westpac’s failures stemmed from inadequate systems and operational breakdowns and the ruling reinforces pressure on lenders to better support financially vulnerable Australians as cost-of-living pressures continue to rise.

While Westpac`s shares slipped following the news and are down year to date, the bank`s stock has lifted close to 40% over the last 5 years.

#stocks #finance #banks #money #fintok